Jerman Michael Allen SEC Filing Summary

Michael Allen Jerman, a director at Inhibitor Therapeutics, Inc. (INTI), acquired 50,000 shares of common stock on May 4, 2026. This acquisition was part of his compensation under the Issuer's 2025 Equity Incentive Plan. The shares were issued as restricted stock. Following this transaction, Mr. Jerman holds a total of 180,411 shares. The transaction code indicates an acquisition, and the price per share was $0.0, consistent with stock awards. The filing was made on a Form 4, with the signature date of June 24, 2026.